NI200900048A - Antagonistas del ccr2 para el tratamiento de la fibrosis. - Google Patents

Antagonistas del ccr2 para el tratamiento de la fibrosis.

Info

Publication number
NI200900048A
NI200900048A NI200900048A NI200900048A NI200900048A NI 200900048 A NI200900048 A NI 200900048A NI 200900048 A NI200900048 A NI 200900048A NI 200900048 A NI200900048 A NI 200900048A NI 200900048 A NI200900048 A NI 200900048A
Authority
NI
Nicaragua
Prior art keywords
fibrosis
treatment
ccr2 antagonists
mcp
antagonist therapy
Prior art date
Application number
NI200900048A
Other languages
English (en)
Inventor
Das Anuk
Murray Lynne
Syed Farhat
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of NI200900048A publication Critical patent/NI200900048A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona terapia de antagonista Anti-MCP-1/CCR2 para el control o la reversión de enfermedades relacionadas a la fibrosis, que incluye, por ej., pero limitado a la terapia de antagonista de MCP-1/CCR2 para la modulación de fabricantes profibroticos asociados con los procesos fibroticos que incluyen la deposición de matriz de colágeno y colapso alveolar.
NI200900048A 2006-10-05 2009-04-02 Antagonistas del ccr2 para el tratamiento de la fibrosis. NI200900048A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82825306P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
NI200900048A true NI200900048A (es) 2010-02-01

Family

ID=39322434

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900048A NI200900048A (es) 2006-10-05 2009-04-02 Antagonistas del ccr2 para el tratamiento de la fibrosis.

Country Status (17)

Country Link
US (1) US20100074886A1 (es)
EP (1) EP2068920A2 (es)
JP (1) JP2010505878A (es)
KR (1) KR20090074787A (es)
CN (1) CN101616689A (es)
AU (1) AU2007319660A1 (es)
BR (1) BRPI0718225A2 (es)
CA (1) CA2665808A1 (es)
CO (1) CO6160339A2 (es)
EA (1) EA200970350A1 (es)
EC (1) ECSP099226A (es)
GT (1) GT200900075A (es)
IL (1) IL198005A0 (es)
MX (1) MX2009003762A (es)
NI (1) NI200900048A (es)
NO (1) NO20091630L (es)
WO (1) WO2008060783A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081785A1 (es) 2007-02-19 2009-01-12 Novartis Ag Derivados de ciclohexil-amida del acido aril carboxilico
CA2734578C (en) 2008-08-18 2019-03-12 Pfizer Inc. Antibodies to ccr2
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
WO2012114223A1 (en) * 2011-02-25 2012-08-30 Pfizer Limited A method of treating liver fibrosis
BR112014023348A2 (pt) * 2012-03-27 2019-03-19 Genentech, Inc. Métodos de prognóstico, de diagnóstico e tratamento
JP2015520768A (ja) * 2012-05-22 2015-07-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 強皮症の処置用の抗−ｃｃｌ２抗体
WO2013192596A2 (en) * 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
JP6401702B2 (ja) 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
RU2724339C2 (ru) * 2014-03-21 2020-06-23 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
EP3386574A4 (en) * 2015-12-11 2019-07-17 Vero Biotech LLC METHOD AND APPARATUS FOR GAS ADMINISTRATION COMPRISING NITRIC OXIDE FOR TREATING FIBROSIS
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR102340352B1 (ko) * 2017-06-27 2021-12-21 주식회사 뉴라클사이언스 섬유증의 치료를 위한 항-fam19a5 항체의 용도
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CN1240699C (zh) * 1999-05-18 2006-02-08 帝人株式会社 与趋化因子有关的疾病的治疗或预防药物
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
CN1469756A (zh) * 2000-10-11 2004-01-21 江头健辅 治疗肝病的药物
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2006085961A2 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
EA200970350A1 (ru) 2009-12-30
KR20090074787A (ko) 2009-07-07
NO20091630L (no) 2009-07-03
CN101616689A (zh) 2009-12-30
BRPI0718225A2 (pt) 2013-11-12
GT200900075A (es) 2010-05-14
MX2009003762A (es) 2009-07-10
WO2008060783A2 (en) 2008-05-22
JP2010505878A (ja) 2010-02-25
IL198005A0 (en) 2011-08-01
EP2068920A2 (en) 2009-06-17
CA2665808A1 (en) 2008-05-22
US20100074886A1 (en) 2010-03-25
ECSP099226A (es) 2009-06-30
WO2008060783A3 (en) 2008-10-23
CO6160339A2 (es) 2010-05-20
AU2007319660A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
NI200900048A (es) Antagonistas del ccr2 para el tratamiento de la fibrosis.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CU20090148A7 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
UY32045A (es) Compuesto amida
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
BRPI0717125B8 (pt) Composto derivado de ftalazinona como forma cristalina a, métodos para obter o mesmo e usos terapêuticos do dito composto
AR070664A1 (es) Sistema para aplicacion de una lente
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
AR064108A1 (es) Tratamiento de ansiedad con eszopiclona
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
AR074818A1 (es) Dihidropiridona-amidas como moduladores de p2x7
CO6531499A2 (es) Uso de ranolazina para el tratameinto de enfermedades cardiovasculares
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
SV2009003315A (es) Nueva utilizacion para el tratamiento de las leucemias
ECSP099759A (es) Compuesto bicíclico y uso farmacéutico del mismo
AR065215A1 (es) Uso de arcillas para el tratamieno de la enfermedad celiaca